photo credit: Cedric Fauntleroy / Pexels

Key Takeaways

• Common medications like metformin and beta-blockers are being studied for their potential to slow cancer growth through biological pathways.
• Observational studies suggest promising links between these drugs and reduced cancer risk or improved survival outcomes.
• Randomized clinical trials have produced mixed results, highlighting the need for further research before clinical adoption.
• Mechanisms such as insulin regulation and stress hormone blocking may explain how these drugs influence cancer biology.
• Drug repurposing offers a cost-effective and faster pathway to expanding cancer treatment options using existing medications.

Dr. Ana Maria Gonzalez-Angulo, MD, is a medical oncologist and clinical researcher with decades of experience studying breast cancer biology, treatment resistance, and translational genomics. Over the course of her career, Ana Maria Gonzalez-Angulo has held academic and research leadership roles at the University of Texas MD https://www.smbceo.com/2026/03/10/dr-jennifer-bath-why-early-detection-matters-in-neurodegenerative-and-cancer-care/ Cancer Center and has collaborated extensively with international research groups. Her work focuses on improving understanding of aggressive breast cancer types, molecular diagnostics, and new therapeutic strategies.

Currently serving as Medical Director of Research and Senior Medical Oncologist at Consultores de Oncologia and as a senior medical oncologist at Unidad de Cancerologia in Guadalajara, Mexico, she continues to contribute to research that explores innovative approaches to cancer treatment, including investigations into how existing medications may influence cancer biology and patient outcomes.

The Potential Use of Metformin and Beta-Blockers in Cancer Treatment

In recent years, scientists have been taking a closer look at older, widely used medications, particularly metformin, a common diabetes drug, and beta-blockers, prescribed for heart conditions, to see whether they might also slow cancer growth. The idea is both practical and exciting: these drugs are inexpensive, familiar to doctors, and generally considered safe. But how strong is the evidence?

Metformin has attracted the most attention. It has been prescribed for type 2 diabetes since the 1950s and is known to lower blood sugar by improving the body’s sensitivity to insulin. The cancer connection first emerged from observational studies. In 2005, a large study from Scotland found that people with diabetes who took metformin had a significantly lower risk of developing cancer compared with those who did not. Since then, multiple observational studies and meta-analyses have reported similar associations, particularly for colorectal, liver, pancreatic, and breast cancers.

Why might this happen? One theory involves insulin. High insulin levels can promote cell growth, and cancer cells are especially responsive to growth signals. By lowering insulin levels, metformin may reduce that stimulus. Laboratory studies also suggest that metformin activates an enzyme called AMPK, which can inhibit a cellular pathway known as mTOR, often overactive in cancer cells. In animal models, metformin has slowed tumor growth.

However, observational studies can only show associations, not proof. People who take metformin may differ in important ways from those who do not. Randomized controlled trials have produced more mixed results. Some trials in breast and colorectal cancer have suggested modest benefits, especially in certain subgroups, while others have not found a clear effect. A large trial known as MA.32, which tested metformin in early-stage breast cancer, reported in 2022 that metformin did not significantly improve invasive disease-free survival overall, although research continues to explore whether specific patients may benefit. In short, metformin remains promising, but not yet a proven anticancer drug.

Beta-blockers tell a similar story. These medications, including drugs like propranolol and atenolol, are commonly used to treat high blood pressure, heart rhythm problems, and anxiety. They work by blocking the effects of stress hormones such as adrenaline. Chronic stress hormones can stimulate tumor growth and help cancer cells spread, at least in laboratory studies. This has led researchers to ask whether blocking these signals might slow cancer progression.

Some observational studies suggest it might. For example, a 2011 study of melanoma patients found that those taking propranolol had a lower risk of recurrence. Other studies have reported improved survival among breast and ovarian cancer patients who were using beta-blockers at the time of diagnosis. A 2018 meta-analysis found that beta-blocker use was associated with improved cancer-specific survival in several cancer types, though results varied.

Again, caution is essential. Many of these findings come from retrospective studies, which can be influenced by confounding factors. Patients on beta-blockers may receive different medical care or have different health profiles. Randomized trials are ongoing, but so far, there is not enough high-quality evidence to recommend beta-blockers specifically as cancer treatments outside of clinical trials.

What makes this field so compelling is the concept of “drug repurposing.” Developing a new cancer drug from scratch can take more than a decade and cost billions of dollars. Older medications already have established safety profiles, which can dramatically shorten that timeline. Even a modest benefit could have a large public health impact if the drug is cheap and widely available.

FAQs

What is the connection between metformin and cancer treatment?

Metformin may influence cancer growth by lowering insulin levels and affecting cellular pathways like AMPK and mTOR, though clinical evidence remains inconclusive.

Can beta-blockers help slow cancer progression?

Beta-blockers may reduce the effects of stress hormones that can promote tumor growth, but current evidence is largely observational and not yet definitive.

Why are observational studies not enough to prove effectiveness?

Observational studies can show associations but cannot control for all variables, meaning differences in patient populations may influence the results.

What is drug repurposing in cancer research?

Drug repurposing involves using existing medications for new therapeutic purposes, offering a faster and more cost-effective approach to treatment development.

Are metformin and beta-blockers currently recommended for cancer treatment?

These drugs are not currently recommended as standard cancer treatments outside of clinical trials, as more rigorous evidence is still needed.

About Ana Maria Gonzalez-Angulo

Ana Maria Gonzalez-Angulo, MD, is a medical oncologist and clinical researcher with extensive experience in breast cancer research and treatment. She previously served as a tenured professor in the Department of Breast Medical Oncology and the Department of Systems Biology at the University of Texas MD Anderson Cancer Center. Currently, she leads clinical research at Consultores de Oncologia and practices as a senior medical oncologist at Unidad de Cancerologia in Guadalajara, Mexico. Her work focuses on aggressive breast cancer types, treatment resistance, translational genomics, and molecular diagnostics.